Showing 5421-5430 of 5909 results for "".
- CorNeat Vision Completes Preclinical Phase For Synthetic Cornea and Scleral Patchhttps://modernod.com/news/corneat-vision-completes-preclinical-phase-for-synthetic-cornea-and-scleral-patch/2479538/CorNeat Vision announced it has completed the preclinical stage of its cornea implant (CorNeat KPro/Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch). The company’s solutions, which also include a glaucoma drainage device, the CorNeat eShunt, will b
- MST Innovations Introduces the Scleral IOL Fixation Solutions Packhttps://modernod.com/news/mst-innovations-introduces-the-scleral-iol-fixation-solutions-pack/2476857/MicroSurgical Technology has introduced the Scleral IOL Fixation Solutions Pack, which is designed to streamline the double-needle scleral IOL fixation technique with several unique new instruments that are conveniently packaged to support the procedure end-to-end. The comprehensive offeri
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du
- iSTAR Medical Announces EUR 40 Million Series C Financinghttps://modernod.com/news/istar-medical-announces-eur-40-million-series-c-financing/2479542/iSTAR Medical announced the completion of a €40m Series C financing to support the development of iSTAR Medical’s MINIject device along the path to commercialization in Europe and the United States. MINIject, an ab-interno MIGS device, provides a powerful and reliable sol
- Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russiahttps://modernod.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia. Terms of the deal were not disc
- OD-OS to Showcase Navilas Navigated Retinal Laser Therapy at EURETINAhttps://modernod.com/news/od-os-to-showcase-navilas-navigated-retinal-laser-therapy-at-euretina/2476852/OD-OS will share clinical experiences with the Navilas 577s digital treatment platform this week at the EURETINA Congress in Paris. Navigated retinal laser therapy with the Navilas 577s allows for panretinal photocoagulation with uniform spot distribution, which is faster and less painful for pat
- Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-completes-enrolment-of-phase-1-clinical-trial-evaluating-thr-687-for-the-treatment-of-dme/2476849/Oxurion NV announced the completion of enrollment of patients in a phase 1 trial with THR-687. The open-label, multicenter, dose escalation phase 1 study is evaluating the safety of a single intravitreal injection of escalating dose levels (3) of THR-687 for the treatment of patients with diabeti
- Alcon Names Carla Mack, OD, Global Head of Professional Affairs for Vision Carehttps://modernod.com/news/alcon-names-carla-mack-od-global-head-of-professional-affairs-for-vision-care/2476847/Alcon has announced that Carla Mack, OD, has been named Global Head, Professional Affairs. In her new role, Dr. Mack leads professional affairs within Alcon’s Global Vision Care Franchise, reporting to Andy Pawson, President and General Manager, Global Vision Care Franchise. As Global Head
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINAhttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-euretina/2476845/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being
- Kowa Submits IND Application to the FDA to Begin Phase 2 Study of Ripasudil Hydrochloride Hydratehttps://modernod.com/news/kowas-submits-ind-application-to-the-fda-to-begin-phase-2-study-of-ripasudil-hydrochloride-hydrate/2476842/Kowa, which has been developing Ripasudil Hydrochloride Hydrate, a Rho kinase inhibitor, for the indication of corneal endothelial diseases, submitted an investigational new drug (IND) application to the FDA on August 30, 2019 in order to commence a phase 2 clinical